News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
The acquisition will strengthen the overall company’s position as leading global CRO services partner
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
Subscribe To Our Newsletter & Stay Updated
